Saturday, March 28, 2015

Amarantus to start Phase 2b with eltoprazine in PD

Amarantus to start Phase 2b with eltoprazine in PD

March 26, 2015 by · Leave a Comment 

Tweet Amarantus BioScience Holdings (OTCQB:AMBS) has an active IND application with the neurology division of the FDA to start a Phase 2b program of eltoprazine for the treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID). The company expects to initiate patient enrollment and dosing in a 60-subject clinical study in individuals with PD in the second […]

Ocular Therapeutix eyeing sustained drug delivery

Ocular Therapeutix eyeing sustained drug delivery

March 17, 2015 by · Leave a Comment 

Tweet Ocular Therapeutix (NASDAQ:OCUL) is aiming to transform the treatment of eye diseases with sustained-release therapeutics, creating a paradigm shift from frequently administered topical ophthalmic drugs to an entire course of therapy in as little as a single dose. “We have multiple late-stage product candidates based on our proven hydrogel technology platform, addressing the largest […]

Ocular Therapeutix posts positive Phase 3a OTX-DP data

Ocular Therapeutix posts positive Phase 3a OTX-DP data

March 10, 2015 by · Leave a Comment 

Tweet Ocular Therapeutix (NASDAQ:OCUL) has announced positive topline data from the first of two Phase 3 clinical trials evaluating the safety and efficacy of its lead product candidate, OTX-DP (sustained release dexamethasone), for the treatment of ocular inflammation and pain following cataract surgery. The Phase 3a study, which enrolled 247 patients, met both primary efficacy […]

Relmada names clinicians, researchers to advisory roles

Relmada names clinicians, researchers to advisory roles

March 5, 2015 by · Leave a Comment 

Tweet Relmada Therapeutics (OTCQB:RLMD) has appointed several leading clinicians and researchers, with expertise in opioid receptors, addiction, psychiatry, neuropathic pain, and clinical trial methodology, to advisory roles. The panel will provide support for planning Relmada’s development programs to advance its pipeline of novel investigational therapies to treat chronic pain. “Their extensive experience and depth of […]

Synergy Disc Replacement sets global sales plan

Synergy Disc Replacement sets global sales plan

March 3, 2015 by · Leave a Comment 

Tweet After an initial market launch of its revolutionary SYNERGY DISC that exceeded expectations in Germany last year, closely-held Synergy Disc Replacement Inc. (SDRI) is planning to expand distribution aggressively in Europe, Asia Pacific and other parts of the world. “We are also in the early stages of developing our U.S. regulatory strategy to gain […]

Dipexium passes 25% enrollment in Locilex Phase 3s

Dipexium passes 25% enrollment in Locilex Phase 3s

February 25, 2015 by · Leave a Comment 

Tweet Dipexium Pharmaceuticals’ (NASDAQ:DPRX) two pivotal Phase 3 clinical trials, known as OneStep-1 and OneStep-2, have passed the 25% enrollment milestone, in the aggregate, with each study having enrolled nearly the same number of patients. The OneStep Phase 3 clinical trials are being conducted under a FDA from the FDA for evaluation of Locilex (pexiganan cream 0.8%), […]

Highland starts Columbia Labs at buy

Highland starts Columbia Labs at buy

February 25, 2015 by · Leave a Comment 

Tweet Highland Research Advisors has initiated coverage of Columbia Laboratories (NASDAQ:CBRX) with a “buy” rating and price target of $14. The stock closed at $6.05 on Tuesday. Columbia is focused on developing products to address the healthcare needs of women and has received FDA approval for six products, including Crinone, a gel containing progesterone that […]

Canaccord starts Avinger at buy

Canaccord starts Avinger at buy

February 24, 2015 by · Leave a Comment 

Tweet Canaccord Genuity has initiated coverage of Avinger (NASDAQ:AVGR) with a “buy” rating and price target of $18. The stock closed at $10.66 on Monday. “Avinger checks the most important boxes that we look for in a small-cap med-tech growth stock,” writes analyst Jason Mills. He said Avinger targets a large, under-penetrated and growing addressable […]

Dipexium has positive skin sensitization data with Locilex

Dipexium has positive skin sensitization data with Locilex

February 17, 2015 by · Leave a Comment 

Tweet Dipexium Pharmaceuticals (NASDAQ:DPRX) has announced successful completion and initial results of DPX-120, a Phase 1 skin sensitization trial of its broad-spectrum topical antibiotic peptide, Locilex. DPX-120 was a double-blind study in healthy adult subjects with the primary objective of evaluating the potential of Locilex cream to induce contact sensitization by repetitive application to human […]

Neovasc launching Reducer in Europe for RA

Neovasc launching Reducer in Europe for RA

February 17, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=LdK0CXdhgDo’]

Tweet Neovasc (NASDAQ:NVCN; TSX:NVC) has begun an initial launch in Europe to introduce its implantable Reducer medical device for the treatment of refractory angina (RA) in advanced-stage cardiovascular patients. “Our aim is have distributors selling Reducer in Switzerland, Italy and the UK, while in Germany, we’ll use a combination of distributors and our own sales […]

Next Page »

Email Newsletters with Constant Contact
Google+